Fig. 1From: Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adultsChanges in mean pancreatic beta cell function (HOMA%β) over 48 weeksBack to article page